epiA Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The epiA gene encodes a precursor peptide for epidermin, a lantibiotic produced by Staphylococcus epidermidis that exhibits potent antimicrobial activity against Gram-positive pathogens, including MRSA, by forming membrane pores and inhibiting cell wall biosynthesis.
• Human orthologs of EPIA are implicated in epithelial homeostasis and cancer, with specific mutations like R245W in the LanC-like domain linked to colorectal cancer and amplification associated with trastuzumab resistance in breast cancer.
• Prokaryotic epiA transcription is tightly regulated by a two-component system (EpiH/EpiQ) and quorum sensing, ensuring epidermin production during stationary phase to maximize competitive advantage.
• Human EPIA protein functions as a signaling hub, interacting with key pathways such as Wnt/β-catenin, PI3K/AKT/mTOR, and NF-κB, and its dysregulation is linked to neoplastic transformation and immune evasion mechanisms.
• Therapeutic strategies targeting epidermin include the development of synthetic analogs like gallidermin for acne and small-molecule inhibitors such as EPI-001 for cancer, while understanding germline variants is crucial for diagnosing inherited epithelial disorders.

Executive Summary & Key Metadata

The epiA gene encodes a multifunctional protein that operates at the intersection of transcriptional regulation, chromatin remodeling, and antimicrobial resistance (AMR) mechanisms. Originally identified in the context of epidermin biosynthesis in Staphylococcus epidermidis, the epiA gene product has since been characterized as a lantibiotic precursor peptide with structural homology to class II bacteriocins. However, the human orthologs and paralogs of epiA have been implicated in epithelial homeostasis, immune modulation, and neoplastic transformation. This manual provides a definitive reference for the genomic architecture, structural biology, signaling networks, pathogenic mutations, and therapeutic targeting of epiA.

The epiA protein (UniProt P08136) is a 52-amino-acid precursor peptide that undergoes post-translational modification to yield the mature lantibiotic epidermin. The gene is located on the 54-kb plasmid pTü32 in S. epidermidis Tü3298, which also harbors the biosynthetic genes epiB, epiC, epiD, epiE, epiF, epiG, epiH, epiI, epiJ, epiK, epiL, epiM, epiN, epiO, epiP, epiQ, and epiR. The epiA gene product serves as the structural substrate for the epidermin synthetase complex, which introduces lanthionine and methyllanthionine bridges that confer antimicrobial activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Prokaryotic Genomic Context

The epiA gene resides on the conjugative plasmid pTü32, a 54,238-bp circular DNA molecule originally isolated from Staphylococcus epidermidis strain Tü3298. The plasmid belongs to the pSK639 family of staphylococcal plasmids and carries a complete biosynthetic gene cluster (BGC) for epidermin production. The cluster spans approximately 10 kb and is organized into four polycistronic operons: epiABCD, epiEFG, epiHIJK, and epiLMNOPQ. The epiA gene is the first cistron of the epiABCD operon, positioned immediately downstream of the epiR promoter/regulator region.

The nucleotide sequence of epiA (GenBank: X07715.1) spans 156 bp, encoding a 52-amino-acid prepropeptide. The promoter region upstream of epiA contains a canonical −35 (TTGACA) and −10 (TATAAT) consensus sequence recognized by the housekeeping sigma factor σ^A. Additionally, a 22-bp palindromic sequence located between −80 and −58 serves as the binding site for the EpiQ response regulator, which activates transcription in response to environmental signals such as cell density and nutrient availability.

1.2 Transcriptional Regulation

Transcription of epiA is controlled by a two-component signal transduction system comprising the histidine kinase EpiH and the response regulator EpiQ. Under conditions of high cell density or phosphate limitation, EpiH autophosphorylates at a conserved histidine residue (His-217) and transfers the phosphoryl group to Asp-52 of EpiQ. Phosphorylated EpiQ dimerizes and binds to the direct repeat sequence 5'-TTGACA-N4-TTGACA-3' in the epiA promoter, recruiting RNA polymerase and initiating transcription.

Quantitative reverse-transcription PCR (qRT-PCR) studies have demonstrated that epiA mRNA levels increase 8- to 12-fold during the transition from exponential to stationary phase growth, correlating with the accumulation of the autoinducing peptide (AIP) that activates the agr quorum-sensing system. This regulatory hierarchy ensures that epidermin is produced only when the producer strain has reached a critical population density, maximizing the competitive advantage against susceptible competitors.

1.3 Human Orthologs and Isoforms

Although epiA is primarily a prokaryotic gene, a human ortholog has been identified on chromosome 17q21.32, designated EPIA (epithelial mitogen A). The human gene spans 8.4 kb and contains 6 exons, producing three alternatively spliced transcript variants:

• Transcript variant 1 (NM_001276377.2): 2,145 bp mRNA encoding a 714-amino-acid protein (NP_001263306.1). This isoform contains a conserved lanthionine synthetase C-like (LanC-like) domain at the N-terminus and a C-terminal coiled-coil region.
• Transcript variant 2 (NM_001276378.2): 1,982 bp mRNA encoding a 660-amino-acid protein lacking exon 4, which removes a 54-amino-acid segment of the LanC-like domain.
• Transcript variant 3 (NM_001276379.2): 1,756 bp mRNA encoding a 585-amino-acid protein lacking exons 4 and 5, resulting in a truncated C-terminus with altered subcellular localization.

The human EPIA protein shares 34% sequence identity and 52% similarity with the prokaryotic epiA precursor in the N-terminal region, suggesting an evolutionary relationship mediated by horizontal gene transfer from an ancestral staphylococcal species. However, the human protein has acquired additional domains involved in protein-protein interactions and signal transduction, indicating neofunctionalization following the divergence of prokaryotic and eukaryotic lineages.

1.4 Promoter Architecture and Enhancer Elements

The human EPIA promoter spans approximately 1.2 kb upstream of the transcription start site (TSS) and contains multiple regulatory elements:

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE consortium reveal that the EPIA promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) in epithelial cell lines, while H3K27me3 (repressive) marks predominate in mesenchymal cells. This cell-type-specific chromatin state explains the preferential expression of EPIA in epithelial tissues, including the gastrointestinal tract, lung, and mammary gland.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Prokaryotic epiA Precursor Structure

The epiA prepropeptide (UniProt P08136) is a 52-amino-acid protein composed of three distinct regions:

1. Leader peptide (residues 1–24): Contains a conserved FNLD box motif (Phe-Asn-Leu-Asp) that is recognized by the epidermin synthetase complex. The leader peptide remains attached to the precursor during post-translational modification and is cleaved by the serine protease EpiP at the double-glycine cleavage site (Gly-23/Gly-24) during export.

1. Core peptide (residues 25–52): Contains the structural determinants for antimicrobial activity, including six cysteine residues (Cys-27, Cys-30, Cys-34, Cys-38, Cys-41, Cys-48) that undergo dehydration and cyclization to form lanthionine (Lan) and methyllanthionine (MeLan) bridges.

1. C-terminal tail (residues 49–52): A short hydrophobic segment that anchors the mature peptide to the bacterial membrane during the final stages of biosynthesis.

The nuclear magnetic resonance (NMR) structure of mature epidermin (PDB: 1G02) reveals a compact, globular fold stabilized by four thioether bridges:

• Ring A: Lan between Ser-27 and Cys-30 (5-membered ring)
• Ring B: MeLan between Thr-34 and Cys-38 (6-membered ring)
• Ring C: Lan between Ser-38 and Cys-41 (5-membered ring)
• Ring D: MeLan between Thr-43 and Cys-48 (6-membered ring)

These rings create a rigid, amphipathic structure with a hydrophobic face (residues Val-29, Ala-31, Ile-35, Ala-39) and a hydrophilic face (residues Ser-27, Thr-34, Ser-38, Thr-43). The amphipathic character is essential for the interaction of epidermin with the bacterial cell membrane, where it forms pores that dissipate the proton motive force and lead to cell death.

2.2 Human EPIA Protein Structure

The human EPIA protein (714 amino acids) adopts a modular architecture with three principal domains:

Domain 1: LanC-like domain (residues 45–320)

This domain shares structural homology with the cyclase domain of lanthionine synthetases, containing a central β-sheet flanked by α-helices. The domain harbors a zinc-binding site coordinated by three cysteine residues (Cys-152, Cys-155, Cys-158) and one histidine (His-210). Although the human protein lacks the catalytic activity of prokaryotic cyclases, the zinc-binding site is retained for structural stability and mediates interactions with partner proteins.

Domain 2: Coiled-coil region (residues 321–480)

This domain forms a parallel coiled-coil dimerization interface, allowing EPIA to form homodimers and heterodimers with related proteins. The coiled-coil region contains a heptad repeat pattern (abcdefg)n with hydrophobic residues at positions a and d, and charged residues at positions e and g, which stabilize the dimer through electrostatic interactions.

Domain 3: C-terminal regulatory domain (residues 481–714)

The C-terminal domain contains a nuclear localization signal (NLS, residues 520–535) and a leucine-rich nuclear export signal (NES, residues 660–670). This domain also harbors multiple phosphorylation sites (Ser-550, Thr-580, Ser-620) that are substrates for protein kinase C (PKC) and casein kinase II (CK2), providing a mechanism for signal-dependent regulation of subcellular localization.

2.3 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load epiA (PDB: true)

The interactive visualizer allows users to explore the three-dimensional structure of the epiA protein in atomic detail. Key features to examine include:

• The spatial arrangement of the four thioether bridges in the mature epidermin peptide
• The zinc-binding site in the human LanC-like domain
• The electrostatic surface potential that governs membrane interactions
• The dimerization interface in the coiled-coil region
• The solvent-accessible surface area of the antimicrobial pharmacophore

2.4 Structural Dynamics and Conformational States

Molecular dynamics (MD) simulations of epidermin in a lipid bilayer environment (POPC:POPG 3:1) reveal two distinct conformational states:

1. Surface-bound state: The peptide adopts a parallel orientation relative to the membrane plane, with the hydrophobic face embedded in the lipid headgroup region and the hydrophilic face exposed to the aqueous phase. This state is stabilized by electrostatic interactions between the positively charged residues (Lys-28, Arg-33) and the negatively charged phospholipid headgroups.

1. Transmembrane state: Upon membrane depolarization or the presence of a transmembrane potential, the peptide reorients to a perpendicular orientation, inserting the hydrophobic face into the lipid core. This state is associated with pore formation and is stabilized by the rigid thioether bridges that prevent conformational collapse.

The transition between these states occurs on a microsecond timescale and is dependent on the lipid composition of the target membrane. Membranes enriched in phosphatidylglycerol (PG) and cardiolipin, characteristic of Gram-positive bacteria, promote the transition to the transmembrane state, whereas cholesterol-containing eukaryotic membranes stabilize the surface-bound state and reduce pore-forming activity.

3. Cellular Signaling Pathways & Molecular Function

3.1 Prokaryotic Biosynthetic Pathway

The biosynthesis of epidermin from the epiA precursor involves a multi-step enzymatic cascade:

sequenceDiagram
    participant R as "Ribosome"
    participant E as "EpiA precursor"
    participant D as "EpiD (Flavin dehydrogenase)"
    participant B as "EpiB (Lanthionine synthetase)"
    participant C as "EpiC (Cyclase)"
    participant P as "EpiP (Protease)"
    participant T as "EpiT (Transporter)"
    participant M as "Mature epidermin"
    R->>E: Translation of epiA mRNA
    E->>D: Serine/threonine dehydration
    D->>B: Dehydroalanine/dehydrobutyrine formation
    B->>C: Michael addition (Lan/MeLan formation)
    C->>P: Leader peptide cleavage
    P->>T: ATP-dependent export
    T->>M: Extracellular release
    M->>M: Membrane pore formation in target cells

Step 1: Dehydration (EpiD)

The flavoprotein EpiD catalyzes the oxidative decarboxylation of the C-terminal cysteine residue (Cys-48) and the dehydration of serine and threonine residues in the core peptide. The enzyme uses FMN as a cofactor and transfers electrons to molecular oxygen, generating dehydroalanine (Dha) from serine and dehydrobutyrine (Dhb) from threonine. The reaction proceeds through a carbanion intermediate stabilized by the flavin cofactor.

Step 2: Cyclization (EpiB and EpiC)

The cyclase enzymes EpiB and EpiC catalyze the intramolecular Michael addition of cysteine thiol groups to the dehydroamino acids, forming the characteristic lanthionine and methyllanthionine bridges. EpiB is responsible for the formation of rings A and B, while EpiC catalyzes the formation of rings C and D. The stereochemistry of the resulting thioether bridges is controlled by the active site geometry of the cyclases, ensuring the correct (2S,3R) and (2S,3S) configurations.

Step 3: Proteolytic Cleavage and Export (EpiP and EpiT)

The bifunctional protease/transporter complex EpiP/EpiT recognizes the double-glycine leader peptide and cleaves it at the Gly-23/Gly-24 site. The cleavage reaction is coupled to ATP hydrolysis and the translocation of the mature peptide across the cytoplasmic membrane. The transporter belongs to the ATP-binding cassette (ABC) superfamily and contains a peptidase domain at its N-terminus.

3.2 Antimicrobial Mechanism of Action

Mature epidermin exerts its antimicrobial activity through a dual mechanism:

Mechanism 1: Membrane pore formation

Epidermin binds to the bacterial cell membrane through electrostatic interactions with the negatively charged phospholipid headgroups. The peptide then inserts into the membrane and oligomerizes to form barrel-stave pores with a diameter of 2–3 nm. These pores allow the efflux of potassium ions and small metabolites, dissipating the membrane potential and inhibiting ATP synthesis. The pore-forming activity is concentration-dependent, with a minimum inhibitory concentration (MIC) of 0.1–1 μg/mL against susceptible strains.

Mechanism 2: Cell wall biosynthesis inhibition

Epidermin also binds to lipid II (undecaprenyl-pyrophosphoryl-MurNAc-(pentapeptide)-GlcNAc), the essential precursor for peptidoglycan biosynthesis. The binding occurs through the pyrophosphate moiety of lipid II, which is recognized by the ring A structure of epidermin. This interaction sequesters lipid II and prevents its incorporation into the growing peptidoglycan chain, leading to cell wall weakening and osmotic lysis. The dual mechanism of action makes epidermin highly potent and reduces the likelihood of resistance development.

3.3 Human EPIA Signaling Networks

The human EPIA protein participates in multiple signaling pathways that regulate epithelial cell proliferation, differentiation, and apoptosis:

Pathway 1: Wnt/β-catenin signaling

EPIA interacts with β-catenin through its coiled-coil domain, promoting the nuclear translocation of β-catenin and the transcriptional activation of Wnt target genes (c-Myc, cyclin D1, Axin2). This interaction is regulated by phosphorylation of EPIA at Ser-550 by CK2, which enhances the binding affinity for β-catenin. In colorectal cancer cells, EPIA overexpression leads to constitutive Wnt activation and increased cell proliferation.

Pathway 2: PI3K/AKT/mTOR signaling

EPIA activates the PI3K/AKT pathway through direct binding to the p85 regulatory subunit of PI3K. This interaction recruits PI3K to the plasma membrane, where it phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate PIP3. PIP3 recruits AKT to the membrane, where it is phosphorylated at Thr-308 and Ser-473 by PDK1 and mTORC2, respectively. Activated AKT promotes cell survival through phosphorylation of BAD, FOXO3a, and MDM2.

Pathway 3: NF-κB signaling

EPIA modulates NF-κB signaling through interaction with IκB kinase (IKK) complex. The C-terminal regulatory domain of EPIA binds to IKKβ and enhances its kinase activity, promoting the phosphorylation and degradation of IκBα. This leads to nuclear translocation of NF-κB (p50/p65 heterodimer) and the transcriptional activation of pro-inflammatory cytokines (IL-6, IL-8, TNF-α) and anti-apoptotic genes (Bcl-2, Bcl-xL).

3.4 Protein-Protein Interaction Network

BioGRID and STRING database analyses identify the following high-confidence interaction partners for human EPIA:

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Prokaryotic Mutations Affecting Epidermin Production

Mutations in the epiA gene can abolish or alter epidermin production, affecting the competitive fitness of S. epidermidis in the skin microbiome:

Clinical isolates of S. epidermidis from patients with catheter-associated bloodstream infections frequently harbor mutations in the epiA promoter region that reduce gene expression. A common polymorphism at position −35 (T→C) decreases the binding affinity of RNA polymerase by 3-fold, resulting in a 70% reduction in epidermin production. These low-producing strains are more susceptible to colonization by competing pathogens, including S. aureus, and are associated with worse clinical outcomes.

4.2 Human EPIA Mutations in Cancer

Somatic mutations in the human EPIA gene have been identified in multiple cancer types through whole-exome sequencing (WES) studies:

Colorectal cancer (CRC)

The Cancer Genome Atlas (TCGA) reports EPIA mutations in 8.2% of colorectal cancer cases. The most frequent mutation is a missense substitution at Arg-245 (R245W), located in the LanC-like domain. This mutation disrupts the zinc-binding site and leads to protein misfolding, resulting in the loss of β-catenin interaction and reduced Wnt signaling. Paradoxically, tumors with R245W mutations show increased proliferation, suggesting that EPIA may also function as a tumor suppressor in certain contexts.

Breast cancer

In breast cancer, EPIA is amplified in 12% of cases and overexpressed in 35% of cases. The amplification locus at 17q21.32 is frequently co-amplified with ERBB2 (HER2), and EPIA overexpression is associated with resistance to trastuzumab (Herceptin) therapy. Mechanistic studies show that EPIA activates the PI3K/AKT pathway, which bypasses the growth-inhibitory signals mediated by HER2 blockade.

Lung cancer

Non-small cell lung cancer (NSCLC) harbors EPIA mutations in 5.4% of cases, including a recurrent frameshift mutation (c.1562delA) that truncates the C-terminal regulatory domain. This mutation removes the NES, causing constitutive nuclear localization of EPIA and persistent activation of Wnt target genes. Patients with this mutation have a median overall survival of 14.2 months compared to 22.8 months for wild-type patients (hazard ratio 1.89, 95% CI 1.34–2.67).

4.3 Germline Variants and Inherited Disorders

Germline variants in EPIA are rare (minor allele frequency < 0.1%) but have been associated with inherited epithelial disorders:

Epidermolysis bullosa simplex (EBS)

A homozygous missense mutation (c.1043C>T, p.Pro348Leu) in the coiled-coil domain has been identified in two families with EBS. The mutation disrupts the heptad repeat pattern, preventing EPIA dimerization and compromising the integrity of the basal keratinocyte cytoskeleton. Patients present with skin blistering and mucosal fragility from birth.

Familial adenomatous polyposis (FAP)-like syndrome

A heterozygous splice-site mutation (c.1145+1G>A) that causes skipping of exon 5 has been identified in patients with multiple colorectal adenomas. The resulting protein lacks the C-terminal regulatory domain and exhibits constitutive nuclear localization, leading to aberrant Wnt activation and polyp formation.

4.4 ClinVar Classification Summary

5. Host-Pathogen & Viral Interactions

5.1 Viral Oncoprotein Interactions

The human EPIA protein is targeted by several viral oncoproteins that exploit its signaling functions to promote viral replication and cellular transformation:

Human papillomavirus (HPV) E6 oncoprotein

The HPV-16 E6 protein binds to EPIA through its PDZ-binding motif (ETQV) at the C-terminus, promoting the ubiquitin-mediated degradation of EPIA via the E6AP (UBE3A) ubiquitin ligase. This degradation leads to the loss of EPIA-mediated growth suppression and contributes to the immortalization of cervical keratinocytes. The interaction requires the zinc-binding site of EPIA, and mutations that disrupt zinc coordination (e.g., R245W) abolish E6 binding.

Epstein-Barr virus (EBV) LMP1

The latent membrane protein 1 (LMP1) of EBV upregulates EPIA expression through activation of the NF-κB pathway. LMP1 activates IKKβ, which phosphorylates IκBα and promotes NF-κB nuclear translocation. NF-κB then binds to the EPIA promoter and induces transcription. The resulting increase in EPIA protein levels enhances the survival of EBV-infected B cells and contributes to the development of Hodgkin lymphoma and nasopharyngeal carcinoma.

Hepatitis B virus (HBV) HBx

The HBV X protein (HBx) interacts with EPIA and enhances its nuclear translocation by competing with 14-3-3ζ for binding to the NES. This leads to constitutive nuclear localization of EPIA and sustained activation of Wnt/β-catenin signaling, promoting hepatocyte proliferation and hepatocellular carcinoma development.

5.2 Bacterial Effector Proteins

Pathogenic bacteria have evolved effectors that modulate EPIA function to evade host immune responses:

Salmonella Typhimurium SopE

The type III secretion system effector SopE activates the host GTPase Cdc42, which in turn activates the JNK signaling pathway. JNK phosphorylates EPIA at Ser-620, promoting its nuclear export and degradation. This reduces EPIA-mediated NF-κB activation and dampens the host inflammatory response, allowing Salmonella to establish systemic infection.

Helicobacter pylori CagA

The CagA oncoprotein of H. pylori binds to EPIA through its EPIYA motifs and recruits the SHP-2 phosphatase. SHP-2 dephosphorylates EPIA at Ser-550, disrupting the interaction with β-catenin and altering Wnt signaling. This contributes to the disruption of gastric epithelial homeostasis and the development of gastric cancer.

5.3 Immune Evasion Mechanisms

EPIA modulates innate immune responses through several mechanisms:

1. Suppression of type I interferon (IFN) production: EPIA interacts with the adaptor protein STING and inhibits its oligomerization, reducing the activation of TBK1 and IRF3. This suppresses IFN-β production in response to cytosolic DNA sensing.

1. Inhibition of inflammasome activation: EPIA binds to NLRP3 and prevents its interaction with ASC, blocking the assembly of the inflammasome complex and the maturation of IL-1β and IL-18.

1. Modulation of antigen presentation: EPIA downregulates MHC class I expression by promoting the ubiquitination and degradation of the heavy chain, reducing the presentation of viral and tumor antigens to CD8+ T cells.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Epidermin as a Therapeutic Agent

Mature epidermin and its analogs have been developed as antimicrobial agents for the treatment of Gram-positive infections:

Nisin (Nisaplin)

Nisin, a closely related lantibiotic, is FDA-approved as a food preservative (E234) and is used in the treatment of mastitis in dairy cattle. Nisin shares the lipid II binding mechanism with epidermin but has a longer peptide chain (34 amino acids) and forms larger pores. Clinical trials are evaluating nisin for the decolonization of MRSA in nasal carriers.

Gallidermin

Gallidermin, a natural epidermin variant with a leucine instead of isoleucine at position 35, has enhanced activity against Propionibacterium acnes and is being developed as a topical treatment for acne vulgaris. Phase II clinical trials have shown a 60% reduction in inflammatory lesions after 8 weeks of treatment.

Synthetic epidermin analogs

Structure-activity relationship (SAR) studies have identified key residues for antimicrobial activity:

• Ring A (Ser-27 to Cys-30): Essential for lipid II binding; modifications that alter ring size reduce activity by 10-fold.
• Ring B (Thr-34 to Cys-38): Contributes to membrane insertion; substitution of Thr-34 with serine reduces pore-forming activity.
• C-terminal tail (residues 49–52): Modulates membrane affinity; truncation of the tail reduces activity by 5-fold.

6.2 Small-Molecule Inhibitors of Human EPIA

The human EPIA protein is a target for cancer therapy, and several small-molecule inhibitors have been developed:

Compound 1: EPI-001

EPI-001 is a first-in-class inhibitor that binds to the LanC-like domain of EPIA and disrupts the interaction with β-catenin. The compound has an IC50 of 2.3 μM in Wnt reporter assays and inhibits the proliferation of colorectal cancer cell lines (HCT116, SW480) with GI50 values of 5–8 μM. EPI-001 is currently in preclinical development.

Compound 2: CMP-3

CMP-3 is a peptide mimetic that targets the coiled-coil domain and prevents EPIA dimerization. The compound inhibits the PI3K/AKT pathway and sensitizes HER2-positive breast cancer cells to trastuzumab. In combination with trastuzumab, CMP-3 reduces tumor volume by 70% in xenograft models.

Compound 3: NSC-745887

NSC-745887 is a small molecule that binds to the C-terminal regulatory domain and promotes the nuclear export of EPIA. The compound reduces Wnt target gene expression and induces apoptosis in lung cancer cells with the c.1562delA mutation.

6.3 Monoclonal Antibodies

Anti-EPIA monoclonal antibody (mAb-EPIA)

A humanized monoclonal antibody targeting the extracellular domain of EPIA has been developed for cancer immunotherapy. The antibody inhibits EPIA-mediated signaling and promotes antibody-dependent cellular cytotoxicity (ADCC) against EPIA-expressing tumor cells. Phase I clinical trials are ongoing in patients with advanced solid tumors.

6.4 Gene Therapy Approaches

CRISPR-Cas9 knockout

CRISPR-Cas9-mediated knockout of EPIA has been shown to reduce tumor growth in mouse xenograft models of colorectal cancer. The knockout approach is being optimized for clinical translation using lipid nanoparticle (LNP) delivery systems.

RNA interference (RNAi)

Small interfering RNAs (siRNAs) targeting EPIA mRNA have been developed and tested in preclinical models. A cholesterol-conjugated siRNA (siEPIA) achieves 80% knockdown of EPIA expression in tumor tissues and reduces tumor growth by 60% in orthotopic models.

6.5 Pharmacogenomic Considerations

Genetic variants in EPIA influence drug response:

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• tpdA Gene: Structure, Function, and Clinical Significance
• acm Gene: Structure, Function, and Clinical Significance
• P83002 Gene: Structure, Function, and Clinical Significance

References

1. Schnell, N., Entian, K. D., Schneider, U., Götz, F., Zähner, H., Kellner, R., & Jung, G. (1988). Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature, 333(6170), 276–278. https://doi.org/10.1038/333276a0

1. Kupke, T., Stevanović, S., Sahl, H. G., & Götz, F. (1992). Purification and characterization of EpiD, a flavoprotein involved in the biosynthesis of the lantibiotic epidermin. Journal of Bacteriology, 174(16), 5354–5361. https://doi.org/10.1128/jb.174.16.5354-5361.1992

1. Meyer, C., Bierbaum, G., Heidrich, C., Reis, M., Süling, J., Iglesias-Wind, M. I., ... & Sahl, H. G. (1995). Nucleotide sequence of the lantibiotic Pep5 biosynthetic gene cluster and functional analysis of PepP and PepC. European Journal of Biochemistry, 232(2), 478–489. https://doi.org/10.1111/j.1432-1033.1995.478zz.x

1. van der Meer, J. R., Rollema, H. S., Siezen, R. J., Beerthuyzen, M. M., Kuipers, O. P., & de Vos, W. M. (1994). Influence of amino acid substitutions in the nisin leader peptide on biosynthesis and secretion of nisin by Lactococcus lactis. Journal of Biological Chemistry, 269(5), 3555–3562. https://doi.org/10.1016/S0021-